Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Jan;65(1):64–73. doi: 10.1172/JCI109661

Effect of Heparin and Heparin Fractions on Platelet Aggregation

Edwin W Salzman 1,2,3, Robert D Rosenberg 1,2,3, Marianne H Smith 1,2,3, Jack N Lindon 1,2,3, Leonard Favreau 1,2,3
PMCID: PMC371340  PMID: 6243142

Abstract

Porcine intestinal mucosal heparin induced aggregation of platelets in citrated platelet-rich plasma and enhanced platelet aggregation and serotonin secretion induced by other agents. This action of heparin was blocked by substances that elevate platelet cyclic AMP and by EDTA but not by inhibitors of platelet cyclooxygenase. The effect was not inhibited by apyrase or by N-amylthio-5′-AMP and therefore did not require the action of ADP, nor was there activation of platelet phospholipase. Platelet aggregation by heparin required a plasma cofactor different from the cofactor required for ristocetin.

Fractionation of heparin yielded preparations that varied in molecular weight and, within a given molecular weight fraction, in affinity for antithrombin III. Fractions of high molecular weight (average 20,000) were more reactive with platelets than were fractions of low molecular weight (7,000). Anticoagulant activity did not parallel the platelet reactivity of heparin fractions. Among high molecular weight fractions, preparations of high or low antithrombin affinity were equally active in induction of platelet aggregation. In low molecular weight fractions, there was an inverse relationship between platelet reactivity and anticoagulant activity in normal platelet-rich plasma, but, in platelet-rich plasma depleted of antithrombin, low molecular weight fractions of high and low antithrombin affinity reacted equally with platelets. These results suggest that formation of an antithrombin-heparin complex protected platelets from aggregation by heparin.

Selection of heparin fractions of low molecular weight and high antithrombin affinity may improve anticoagulant therapy and development of thromboresistant heparin-coated artificial materials.

Full text

PDF
65

Images in this article

67Image
on p.67

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson L. O., Barrowcliffe T. W., Holmer E., Johnson E. A., Sims G. E. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res. 1976 Dec;9(6):575–583. doi: 10.1016/0049-3848(76)90105-5. [DOI] [PubMed] [Google Scholar]
  2. Ardlie N. G., Perry D. W., Packham M. A., Mustard J. F. Influence of apyrase on stability of suspensions of washed rabbit platelets. Proc Soc Exp Biol Med. 1971 Apr;136(4):1021–1023. doi: 10.3181/00379727-136-35419. [DOI] [PubMed] [Google Scholar]
  3. BORN G. V., CROSS M. J. THE AGGREGATION OF BLOOD PLATELETS. J Physiol. 1963 Aug;168:178–195. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Babcock R. B., Dumper C. W., Scharfman W. B. Heparin-induced immune thrombocytopenia. N Engl J Med. 1976 Jul 29;295(5):237–241. doi: 10.1056/NEJM197607292950501. [DOI] [PubMed] [Google Scholar]
  5. Baird R. A., Convery R. Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia. J Bone Joint Surg Am. 1977 Dec;59(8):1061–1064. [PubMed] [Google Scholar]
  6. Baumgartner H. R., Stemerman M. B., Spaet T. H. Adhesion of blood platelets to subendothelial surface: distinct from adhesion to collagen. Experientia. 1971 Mar 15;27(3):283–285. doi: 10.1007/BF02138148. [DOI] [PubMed] [Google Scholar]
  7. Bell W. R., Tomasulo P. A., Alving B. M., Duffy T. P. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med. 1976 Aug;85(2):155–160. doi: 10.7326/0003-4819-85-2-155. [DOI] [PubMed] [Google Scholar]
  8. Berger S., Salzman E. W. Thromboembolic complication of prosthetic devices. Prog Hemost Thromb. 1974;2(0):273–309. [PubMed] [Google Scholar]
  9. Besterman E. M., Gillett M. P. Heparin effects on plasma lysolecithin formation and platelet aggregation. Atherosclerosis. 1973 May-Jun;17(3):503–513. doi: 10.1016/0021-9150(73)90040-3. [DOI] [PubMed] [Google Scholar]
  10. Coller B. S., Franza B. R., Jr, Gralnick H. R. The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH. Blood. 1976 May;47(5):841–854. [PubMed] [Google Scholar]
  11. Coller B. S., Gralnick H. R. Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J Clin Invest. 1977 Aug;60(2):302–312. doi: 10.1172/JCI108778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Damus P. S., Rosenberg R. D. Antithrombin-heparin cofactor. Methods Enzymol. 1976;45:653–669. doi: 10.1016/s0076-6879(76)45056-5. [DOI] [PubMed] [Google Scholar]
  13. Eika C. Inhibition of thrombin induced aggregation of human platelets by heparin. Scand J Haematol. 1971;8(3):216–222. doi: 10.1111/j.1600-0609.1971.tb01976.x. [DOI] [PubMed] [Google Scholar]
  14. Eika C. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol. 1972;9(3):248–257. doi: 10.1111/j.1600-0609.1972.tb00937.x. [DOI] [PubMed] [Google Scholar]
  15. Eika C. The platelet aggregating effect of eight commercial heparins. Scand J Haematol. 1972;9(5):480–482. doi: 10.1111/j.1600-0609.1972.tb00973.x. [DOI] [PubMed] [Google Scholar]
  16. Ellison N., Edmunds L. H., Jr, Colman R. W. Platelet aggregation following heparin and protamine administration. Anesthesiology. 1978 Jan;48(1):65–68. doi: 10.1097/00000542-197801000-00008. [DOI] [PubMed] [Google Scholar]
  17. Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
  18. Fratantoni J. C., Pollet R., Gralnick H. R. Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood. 1975 Mar;45(3):395–401. [PubMed] [Google Scholar]
  19. Friedman L. I., Liem H., Grabowski E. F., Leonard E. F., McCord C. W. Inconsequentiality of surface properties for initial platelet adhesion. Trans Am Soc Artif Intern Organs. 1970;16:63–73. [PubMed] [Google Scholar]
  20. GOLLUB S., ULIN A. W. Heparin-induced thrombocytopenia in man. J Lab Clin Med. 1962 Mar;59:430–435. [PubMed] [Google Scholar]
  21. Gillett M. P., Besterman E. M. Letter: Effects of heparin derived from different tissues on plasma-phospholipids and platelet aggregation. Lancet. 1973 Nov 24;2(7839):1204–1205. doi: 10.1016/s0140-6736(73)92966-8. [DOI] [PubMed] [Google Scholar]
  22. Green D., Harris K., Reynolds N., Roberts M., Patterson R. Heparin immune thrombocytopenia: evidence for a heparin-platelet complex as the antigenic determinant. J Lab Clin Med. 1978 Jan;91(1):167–175. [PubMed] [Google Scholar]
  23. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  24. Lagergren H. R., Eriksson J. C. Plastics with a stable surface monolayer of cross-linked heparin: preparation and evaluation. Trans Am Soc Artif Intern Organs. 1971;17:10–12. [PubMed] [Google Scholar]
  25. Lam L. H., Silbert J. E., Rosenberg R. D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun. 1976 Mar 22;69(2):570–577. doi: 10.1016/0006-291x(76)90558-1. [DOI] [PubMed] [Google Scholar]
  26. Lane D. A., Macgregor I. R., Michalski R., Kakkar V. V. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res. 1978 Feb;12(2):257–271. doi: 10.1016/0049-3848(78)90297-9. [DOI] [PubMed] [Google Scholar]
  27. Lapetina E. G., Schmitges C. J., Chandrabose K., Cuatrecases P. Cyclic adenosine 3',5'-monophosphate and prostacyclin inhibit membrane phospholipase activity in platelets. Biochem Biophys Res Commun. 1977 Jun 6;76(3):828–835. doi: 10.1016/0006-291x(77)91575-3. [DOI] [PubMed] [Google Scholar]
  28. Laurent T. C., Tengblad A., Thunberg L., Hök M., Lindahl U. The molecular-weight-dependence of the anti-coagulant activity of heparin. Biochem J. 1978 Nov 1;175(2):691–701. doi: 10.1042/bj1750691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lindon J. N., Rodvien R., Brier D., Greenberg R., Merrill E., Salzman E. W. In vitro assessment of interaction of blood with model surfaces. J Lab Clin Med. 1978 Dec;92(6):904–915. [PubMed] [Google Scholar]
  30. Lindon J. N., Rodvien R., Waugh D. F. Effects of matrix contact during gel filtration of human platelets in plasma. Thromb Haemost. 1976 Nov 30;36(2):311–318. [PubMed] [Google Scholar]
  31. Lindon J., Rosenberg R., Merrill E., Salzman E. Interaction of human platelets with heparinized agarose gel. J Lab Clin Med. 1978 Jan;91(1):47–59. [PubMed] [Google Scholar]
  32. Lindsay R. M., Prentice C. R., Davidson J. F., Burton J. A., McNicol G. P. Haemostatic changes during dialysis associated with thrombus formation on dialysis membranes. Br Med J. 1972 Nov 25;4(5838):454–458. doi: 10.1136/bmj.4.5838.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lindsay R. M., Rourke J. T., Reid B. D., Linton A. L., Gilchrist T., Courtney J., Edwards R. O. The role of heparin on platelet retention by acrylonitrile co-polymer dialysis membranes. J Lab Clin Med. 1977 Apr;89(4):724–734. [PubMed] [Google Scholar]
  34. McMillan R. M., MacIntyre D. E., Gordon J. L. Simple, sensitive fluorimetric assay for malondialdehyde production by blood platelets. Thromb Res. 1977 Sep;11(3):425–428. doi: 10.1016/0049-3848(77)90194-3. [DOI] [PubMed] [Google Scholar]
  35. Najjar F. B., Gott V. L. The use of small-diameter Dacron grafts with wall-bonded heparin for venous and arterial replacement: canine studies and preliminary clinical experience. Surgery. 1970 Dec;68(6):1053–1063. [PubMed] [Google Scholar]
  36. Natelson E. A., Lynch E. C., Alfrey C. P., Jr, Gross J. B. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann Intern Med. 1969 Dec;71(6):1121–1125. doi: 10.7326/0003-4819-71-6-1121. [DOI] [PubMed] [Google Scholar]
  37. Nelson J. C., Lerner R. G., Goldstein R., Cagin N. A. Heparin-induced thrombocytopenia. Arch Intern Med. 1978 Apr;138(4):548–552. [PubMed] [Google Scholar]
  38. O'Brien J. R., Shoobridge S. M., Finch W. J. Comparison of the effect of heparin and citrate on platelet aggregation. J Clin Pathol. 1969 Jan;22(1):28–31. doi: 10.1136/jcp.22.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Olivecrona T., Bengtsson G., Marklund S. E., Lindahl U., Hök M. Heparin-lipoprotein lipase interactions. Fed Proc. 1977 Jan;36(1):60–65. [PubMed] [Google Scholar]
  40. ROBERTS B., ROSATO F. E., ROSATO E. F. HEPARIN--A CAUSE OF ARTERIAL EMBOLI? Surgery. 1964 Jun;55:803–808. [PubMed] [Google Scholar]
  41. Rhodes G. R., Dixon R. H., Silver D. Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications. Ann Surg. 1977 Dec;186(6):752–758. doi: 10.1097/00000658-197712000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Rosenberg R. D. Actions and interactions of antithrombin and heparin. N Engl J Med. 1975 Jan 16;292(3):146–151. doi: 10.1056/NEJM197501162920307. [DOI] [PubMed] [Google Scholar]
  43. Rosenberg R. D., Armand G., Lam L. Structure-function relationships of heparin species. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3065–3069. doi: 10.1073/pnas.75.7.3065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rosenberg R. D., Jordan R. E., Favreau L. V., Lam L. H. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun. 1979 Feb 28;86(4):1319–1324. doi: 10.1016/0006-291x(79)90260-2. [DOI] [PubMed] [Google Scholar]
  45. Rosenberg R. D., Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1218–1222. doi: 10.1073/pnas.76.3.1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. SALZMAN E. W. THE LIMITATIONS OF HEPARIN THERAPY AFTER ARTERIAL RECONSTRUCTION. Surgery. 1965 Jan;57:131–138. [PubMed] [Google Scholar]
  47. SPAET T. H., ZUCKER M. B. MECHANISM OF PLATELET PLUG FORMATION AND ROLE OF ADENOSINE DIPHOSPHATE. Am J Physiol. 1964 Jun;206:1267–1274. doi: 10.1152/ajplegacy.1964.206.6.1267. [DOI] [PubMed] [Google Scholar]
  48. Salzman E. W., Lindon J. N., Rodvien R. Cyclic AMP in human blood platelets: relation to platelet prostaglandin synthesis induced by centrifugation or surface contact. J Cyclic Nucleotide Res. 1976;2(1):25–37. [PubMed] [Google Scholar]
  49. Schmer G., Teng L. N., Cole J. J., Vizzo J. E., Francisco M. M., Scribner B. H. Successful use of a totally heparin grafted hemodialysis system in sheep. Trans Am Soc Artif Intern Organs. 1976;22:654–663. [PubMed] [Google Scholar]
  50. Shanberge J. N., Kambayashi J., Nakagawa M. The interaction of platelets with a tritium-labelled heparin. Thromb Res. 1976 Dec;9(6):595–609. doi: 10.1016/0049-3848(76)90107-9. [DOI] [PubMed] [Google Scholar]
  51. Shen L. L., Barlow G. H., Holleman W. H. Differential activities of heparins in human plasma and in sheep plasma. Effects of heparin molecular sizes and sources. Thromb Res. 1978 Oct;13(4):671–679. doi: 10.1016/0049-3848(78)90156-1. [DOI] [PubMed] [Google Scholar]
  52. Tangen O., Berman H. J., Marfey P. Gel filtration. A new technique for separation of blood platelets from plasma. Thromb Diath Haemorrh. 1971 Jun 30;25(2):268–278. [PubMed] [Google Scholar]
  53. Thomson C., Forbes C. D., Prentice C. R. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med. 1973 Oct;45(4):485–494. doi: 10.1042/cs0450485. [DOI] [PubMed] [Google Scholar]
  54. Timmons S., Hawiger J. Separation of human platelets from plasma proteins including factor VIII VWF by a combined albumin gradient-gel filtration method using HEPES buffer. Thromb Res. 1978 Feb;12(2):297–306. doi: 10.1016/0049-3848(78)90300-6. [DOI] [PubMed] [Google Scholar]
  55. Valiathan M. S., Weldon C. S., Bender H. W., Jr, Topaz S. R., Gott V. L. Resection of aneurysms of the descending thoracic aorta using a GBH-coated shunt bypass. J Surg Res. 1968 May;8(5):197–205. doi: 10.1016/0022-4804(68)90086-3. [DOI] [PubMed] [Google Scholar]
  56. WEISMANN R. E., TOBIN R. W. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg. 1958 Feb;76(2):219–227. doi: 10.1001/archsurg.1958.01280200041005. [DOI] [PubMed] [Google Scholar]
  57. Whigham K. A., Drummond A. H., Edgar W., Prentice C. R. A method for the removal of platelet aggregating activity of commercial apyrase. Thromb Haemost. 1976 Dec 31;36(3):652–653. [PubMed] [Google Scholar]
  58. Zucker M. B. Heparin and platelet function. Fed Proc. 1977 Jan;36(1):47–49. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES